Greenwich LifeSciences (GLSI) Projected to Post Quarterly Earnings on Friday

Greenwich LifeSciences (NASDAQ:GLSI) is expected to be posting its Q3 2026 results on Friday, November 13th. Analysts expect the company to post earnings of ($0.30) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Greenwich LifeSciences (NASDAQ:GLSI) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.06. On average, analysts expect Greenwich LifeSciences to post ($1.29) EPS for the current fiscal year and ($1.17) EPS for the next fiscal year.

Greenwich LifeSciences Price Performance

Shares of GLSI stock opened at $16.09 on Thursday. The company’s fifty day simple moving average is $16.59 and its two-hundred day simple moving average is $21.23. Greenwich LifeSciences has a 1 year low of $7.78 and a 1 year high of $34.10. The stock has a market capitalization of $236.17 million, a price-to-earnings ratio of -10.45 and a beta of 1.57.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GLSI. HC Wainwright raised their price target on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings lowered Greenwich LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Greenwich LifeSciences has a consensus rating of “Hold” and an average target price of $69.00.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies designed to reduce the risk of breast cancer recurrence. The company’s lead product candidate is GLSI-100, an investigational vaccine combining the HER2-derived peptide GP2 with granulocyte-macrophage colony-stimulating factor (GM-CSF). GLSI-100 is being developed as an adjuvant therapy for patients with HER2-positive breast cancer who have completed standard treatment, including trastuzumab.